Preclinical Pharmacokinetics and In Vitro Metabolism of BMS-690514, a Potent Inhibitor of EGFR and VEGFR2

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

Robert J. Motzer, M. Dror Michaelson, Bruce G. Redman et al. · Journal of Clinical Oncology · 2005 · 1.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic<i>EGFR</i>Mutations

Lecia V. Sequist, Renato Martins, David R. Spigel et al. · Journal of Clinical Oncology · 2008 · 834 citations · Full text

Medicine, Oncology, Pharmacology +17

THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVE

Thorir D. Bjornsson, John T. Callaghan, Heidi J. Einolf et al. · Drug Metabolism and Disposition · 2003 · 784 citations

Medicine, Pharmacokinetics, Pharmacology +17

The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data

Kaoxiang Sun · Chinese New Drugs Journal · 2005 · 764 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data.

R. Scott Obach, James G. Baxter, Theodore E. Liston et al. · PubMed · 1997 · 638 citations

Pharmacy, Pharmacokinetics, Pharmacology +14